Navigation Links
S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
Date:5/4/2010

r cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors.ONX 0801, a targeted alpha-folate inhibitor, is currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

Forward-Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of SB1518 (ONX 0803) and SB1578 (ONX 0805).  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 20
'/>"/>

SOURCE S*BIO Pte Ltd; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
2. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Completes US$26 Million Equity Financing
5. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
6. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
7. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
8. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
9. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...   Meditope Biosciences, Inc ., a biotechnology company ... announced presentation of data demonstrating the use of its ... (ADCs). The data were presented in an abstract at the ... Philadelphia . "We ... the many commercial applications that may be possible for ...
(Date:4/20/2015)... Whitehouse Laboratories is pleased and overly excited ... Food and Drug Administration (FDA) inspection and received no ... GMP compliance inspection, as based upon 21CFR Parts 210 ... 6th and was granted NAI (no action indicated) status. ... Good Manufacturing Practice (GMP) quality system required by the ...
(Date:4/17/2015)... Calif. , April 17, 2015 /PRNewswire/ ... received a SBIR grant from the National ... National Institutes of Health (NIH). The grant ... efforts in the development of breakthrough genomic ... using specially fabricated substrates. Centrillion has been ...
(Date:4/17/2015)... April 17, 2015 CIO Review ( ... its 20 Most Promising Pharma and Life Science Technology ... MediSpend global compliance software platform for life sciences companies. ... by a panel of experts and members of CIO ... “MMIS’s MediSpend Platform has been on our radar for ...
Breaking Biology Technology:Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2
... Nikon-Exclusive Perfect Focus System and High-Speed Motorization Meets ... and Pharmaceutical Science Research Needs, MELVILLE, N.Y., ... has combined streamlined component automation,with speeds more than ... launch of the Eclipse Ti-E inverted research microscope. ...
... ... - Third Quarter EPS of $0.70 per Basic Share, or $0.66 per Diluted Share, - ... ... United,Therapeutics Corporation (Nasdaq: UTHR ) today announced its results of,operations for the quarter ended September ...
... Biosciences,Inc. (Nasdaq: NBIX ) today announced that it ... and commercialization of indiplon,in Japan with Dainippon Sumitomo Pharma ... (NDA) for indiplon in the US for the,treatment of ... FDA with a,PUDFA action date of December 12, 2007. ...
Cached Biology Technology:Nikon Instruments Launches New Eclipse Ti-E Fully-Integrated, Motorized Inverted Microscope 2Nikon Instruments Launches New Eclipse Ti-E Fully-Integrated, Motorized Inverted Microscope 3United Therapeutics Reports Third Quarter 2007 Financial Results 2United Therapeutics Reports Third Quarter 2007 Financial Results 3United Therapeutics Reports Third Quarter 2007 Financial Results 4United Therapeutics Reports Third Quarter 2007 Financial Results 5United Therapeutics Reports Third Quarter 2007 Financial Results 6United Therapeutics Reports Third Quarter 2007 Financial Results 7United Therapeutics Reports Third Quarter 2007 Financial Results 8United Therapeutics Reports Third Quarter 2007 Financial Results 9Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan 2Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan 3
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... from Holzmaden (Germany) that perished 182 million years ago ... the extinct marine reptile is almost immaculately preserved and ... in their anatomical position. The bones of the ichthyosaur ... part, they lie scattered outside the body of the ...
... proceeds very slowly. But the slow-growing bacteria living many ... global storage of organic carbon and have a long-term effect ... the University of Rhode Island have developed a new method ... Their findings were published last week in the ...
... the Woods Hole Oceanographic Institution (WHOI), University of Hawaii, ... systematic study of life in the deepest marine habitat ... floor ranging from 19,685 to 36,089 feet (6,000 to ... the technical challenges involved in reaching this depth, known ...
Cached Biology News:Exploding dinosaur hypothesis implodes 2Oceanographers develop method for measuring the pace of life in deep sediments 2WHOI researchers, collaborators receive $1.4 million grant to study life in ocean's greatest depths 2WHOI researchers, collaborators receive $1.4 million grant to study life in ocean's greatest depths 3WHOI researchers, collaborators receive $1.4 million grant to study life in ocean's greatest depths 4
... a full length insert sequencing service for ... and fosmids. Agencourt utilizes unique library ... There are several features that allow ... with rapid turnaround including our patented magnetic ...
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
... Fully automated, GLP-compliant Facility , Galaxy LIMS, ... , Highly experienced scientists ,We offer individual ... or full plasmids for single or double ... used when the DNA of interest is ...
Great for biotinylating DNA/RNA probes...
Biology Products: